Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model

Genomics

Volumn 92, Issue 6, 2008, Pages 419-428

  Rhee, Dong Keun ^a   Park, Su Hyung ^a   Jang, Yeun Kyu ^a  

^a Yonsei University   (South Korea)

Author keywords

Epigenetic inactivation; Isogenic human breast cancer cell lines; Molecular signatures; Progression; S100 calcium binding protein family; Transformation

Indexed keywords

CALGRANULIN A; CALGRANULIN B; CALVASCULIN; KALLIKREIN; KALLIKREIN 5; LYMPHOCYTE ANTIGEN; PROTEIN TNFSF7; PSORIASIN; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CARCINOMA IN SITU; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; INVASIVE CARCINOMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, GENETIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 55949108653     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2008.08.005     Document Type: Article

References (67)

1. Becker M., Sommer A., Kratzschmar J.R., Seidel H., Pohlenz H.D., and Fichtner I. Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol. Cancer Ther. 4 (2005) 151-168
2. Grander D. How do mutated oncogenes and tumor suppressor genes cause cancer?. Med. Oncol. 15 (1998) 20-26
3. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
4. Tysnes B.B., and Bjerkvig R. Cancer initiation and progression: involvement of stem cells and the microenvironment. Biochim. Biophys. Acta 1775 (2007) 283-297
5. Lodish H., Berk A., Zipursky L., Matsudaira P., Baltimore D., and Darnell J. Mol. Cell. Biol. (1999), W. H. Freeman and Company, New York
6. Ellsworth R.E., Ellsworth D.L., Deyarmin B., Hoffman L.R., Love B., Hooke J.A., et al. Timing of critical genetic changes in human breast disease. Ann. Surg. Oncol. 12 (2005) 1054-1060
7. Arpino G., Laucirica R., and Elledge R.M. Premalignant and in situ breast disease: biology and clinical implications. Ann. Intern. Med. 143 (2005) 446-457
8. Abramovitz M., and Leyland-Jones B. Application of array-based genomic and epigenomic technologies to unraveling the heterogeneous nature of breast tumors: on the road to individualized treatment. Cancer Genomics Proteomics 4 (2007) 135-145
9. Brennan D.J., Kelly C., Rexhepaj E., Dervan P.A., Duffy M.J., and Gallagher W.M. Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer. Cancer Genomics Proteomics 4 (2007) 121-134
10. Nagaraja G.M., Othman M., Fox B.P., Alsaber R., Pellegrino C.M., Zeng Y., et al. Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 25 (2006) 2328-2338
11. Rhodes D.R., Kalyana-Sundaram S., Mahavisno V., Varambally R., Yu J., Briggs B.B., Barrette T.R., Anstet M.J., Kincead-Beal C., Kulkarni P., et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9 (2007) 166-180
12. Yao R., Yi Y., Grubbs C.J., Lubet R.A., and You M. Gene expression profiling of chemically induced rat bladder tumors. Neoplasia 9 (2007) 207-221
13. Khan J., Wei J.S., Ringner M., Saal L.H., Ladanyi M., Westermann F., et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat. Med. 7 (2001) 673-679
14. Soule H.D., Maloney T.M., Wolman S.R., Peterson W.D., Brenz Jr. R., McGrath C.M., et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 50 (1990) 6075-6086
15. Miller F.R., Soule H.D., Tait L., Pauley R.J., Wolman S.R., Dawson P.J., et al. Xenograft model of progressive human proliferative breast disease. J. Natl. Cancer Inst. 85 (1993) 1725-1732
16. Dawson P.J., Wolman S.R., Tait L., Heppner G.H., and Miller F.R. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am. J. Pathol. 148 (1996) 313-319
17. Miller F.R., Santner S.J., Tait L., and Dawson P.J. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J. Natl. Cancer Inst. 92 (2000) 1185-1186
18. Strickland L.B., Dawson P.J., Santner S.J., and Miller F.R. Progression of premalignant MCF10AT generates heterogeneous malignant variants with characteristic histologic types and immunohistochemical markers. Breast Cancer Res. Treat. 64 (2000) 235-240
19. Santner S.J., Dawson P.J., Tait L., Soule H.D., Eliason J., Mohamed A.N., et al., Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res. Treat. 65 (2001) 101-110
20. Worsham M.J., Pals G., Schouten J.P., Miller F.R., Tiwari N., van Spaendonk R., et al. High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model. Breast Cancer Res. Treat. 96 (2006) 177-186
21. Baylin S.B., and Jones P.A. Epigenetic determinants of cancer. In: Allis C.D., Jenuwein T., and Reinberg D. (Eds). Epigenetics (2007), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York 457-476
22. Robertson K.D. DNA methylation and human disease. Nat. Rev. Genet. 6 (2005) 597-610
23. Rath G.M., Schneider C., Dedieu S., Rothhut B., Soula-Rothhut M., Ghoneim C., et al. The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicin-induced apoptosis in human thyroid carcinoma cells. Biochim. Biophys. Acta 1763 (2006) 1125-1134
24. Roberts D.D., Isenberg J.S., Ridnour L.A., and Wink D.A. Nitric oxide and its gatekeeper thrombospondin-1 in tumor angiogenesis. Clin. Cancer Res. 13 (2007) 795-798
25. Jachimczak P., Apfel R., Bosserhoff A.K., Fabel K., Hau P., Tschertner I., et al. Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques. Int. J. Cancer 113 (2005) 88-92
26. Chen L., O'Bryan J.P., Smith H.S., and Liu E. Overexpression of matrix Gla protein mRNA in malignant human breast cells: isolation by differential cDNA hybridization. Oncogene 5 (1990) 1391-1395
27. Han W., Ding P., Xu M., Wang L., Rui M., Shi S., et al. Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics 81 (2003) 609-617
28. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr. Relat. Cancer 13 (2006) 1033-1067
29. Carles A., Millon R., Cromer A., Ganguli G., Lemaire F., Young J., et al. Head and neck squamous cell carcinoma transcriptome analysis by comprehensive validated differential display. Oncogene 25 (2006) 1821-1831
30. Michael I.P., Sotiropoulou G., Pampalakis G., Magklara A., Ghosh M., Wasney G., et al. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J. Biol. Chem. 280 (2005) 14628-14635
31. Santamaria I., Velasco G., Cazorla M., Fueyo A., Campo E., and Lopez-Otin C. Cathepsin L2, a novel human cysteine proteinase produced by breast and colorectal carcinomas. Cancer Res. 58 (1998) 1624-1630
32. Fritzsche S., Kenzelmann M., Hoffmann M.J., Muller M., Engers R., Grone H.J., et al. Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr. Relat. Cancer 13 (2006) 839-849
33. Gray-Owen S.D., and Blumberg R.S. CEACAM1: contact-dependent control of immunity. Nat. Rev. Immunol. 6 (2006) 433-446
34. Neubauer A., Fiebeler A., Graham D.K., O'Bryan J.P., Schmidt C.A., Barckow P., et al. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 84 (1994) 1931-1941
35. O'Bryan J.P., Frye R.A., Cogswell P.C., Neubauer A., Kitch B., Prokop C., et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol. Cell. Biol. 11 (1991) 5016-5031
36. Grusch M., Drucker C., Peter-Vorosmarty B., Erlach N., Lackner A., Losert A., et al. Deregulation of the activin/follistatin system in hepatocarcinogenesis. J. Hepatol. 45 (2006) 673-680
37. Chenais B., Derjuga A., Massrieh W., Red-Horse K., Bellingard V., Fisher S.J., et al. Functional and placental expression analysis of the human NRF3 transcription factor. Mol. Endocrinol. 19 (2005) 125-137
38. Winkles J.A., Tran N.L., and Berens M.E. TWEAK and Fn14: new molecular targets for cancer therapy?. Cancer Lett. 235 (2006) 11-17
39. Cheng Y., and Lotan R. Molecular cloning and characterization of a novel retinoic acid-inducible gene that encodes a putative G protein-coupled receptor. J. Biol. Chem. 273 (1998) 35008-35015
40. Park B.K., Zhang H., Zeng Q., Dai J., Keller E.T., Giordano T., et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat. Med. 13 (2007) 62-69
41. Uemura Y., Kobayashi M., Nakata H., Kubota T., Saito T., Bandobashi K., et al. Effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on lung cancer: roles of cyclooxygenase-2. Oncol. Rep. 17 (2007) 955-961
42. Wysoczynski M., Miekus K., Jankowski K., Wanzeck J., Bertolone S., Janowska-Wieczorek A., et al. Leukemia inhibitory factor: a newly identified metastatic factor in rhabdomyosarcomas. Cancer Res. 67 (2007) 2131-2140
43. Ramakulov A., Lein M., Johannsen M., Schrader M., Miller K., and Jung K. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas. Cancer Sci. 99 (2008) 1188-1194
44. Kodama J., Hasengaowa, Kusumoto T., Seki N., Matsuo T., Ojima Y., et al. Prognostic significance of stromal versican expression in human endometrial cancer. Ann. Oncol. 18 (2007) 269-274
45. Chiquet-Ehrismann R., Mackie E.J., Pearson C.A., and Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 47 (1986) 131-139
46. Scott D.K., Lord R., Muller H.K., Malley R.C., and Woods G.M. Proteomics identifies enhanced expression of stefin A in neonatal murine skin compared with adults: functional implications. Br. J. Dermatol. 156 (2007) 1156-1162
47. Schagdarsurengin U., Pfeifer G.P., and Dammann R. Frequent epigenetic inactivation of cystatin M in breast carcinoma. Oncogene 26 (2007) 3089-3094
48. Lingbao A., Kim W., Kim T., Fields C.R., Massoll, Robertson K.D., and Brown K.D. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res. 66 (2006) 7899-7909
49. Chen J., Lam S., Pilon A., McWilliams A., Melby J., and Szabo E. The association between the anti-inflammatory protein CC10 and smoking status among participants in a chemoprevention trial. Cancer Epidemiol. Biomark. Prev. 16 (2007) 577-583
50. Hintzen R.Q., Lens S.M., Beckmann M.P., Goodwin R.G., Lynch D., and van Lier R.A. Characterization of the human CD27 ligand, a novel member of the TNF gene family. J. Immunol. 152 (1994) 1762-1773
51. Xu J., Zhou J.Y., Tainsky M.A., and Wu G.S. Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2′-deoxycytidine sensitizes human breast cancer cells to adriamycin. Cancer Res. 67 (2007) 1203-1211
52. Alvarez-Medina R., Cayuso J., Okubo T., Takada S., and Marti E. Wnt canonical pathway restricts graded Shh/Gli patterning activity through the regulation of Gli3 expression. Development 135 (2008) 237-247
53. Hartmann L.C., Keeney G.L., Lingle W.L., Christianson T.J., Varghese B., Hillman D., Oberg A.L., and Low P.S. Folate receptor overexpression is associated with poor outcome in breast cancer. Int. J. Cancer 121 (2007) 938-942
54. Manitz M., Horst B., Seeliger S., Strey A., Skryabin B.V., et al. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol. Cell. Biol. 23 (2003) 1034-1043
55. Yui S., Nakatani Y., and Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol. Pharm. Bull. 26 (2003) 753-760
56. Cross S.S., Hamdy F.C., Deloulme J.C., and Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overepxressed in common cancers. Histopathology 46 (2005) 256-269
57. El-Rifai W., Moskaluk C.A., Abdrabbo M.K., Harper J., Yoshida C., Riggins Jr. G.J., Frierson, and Powell S.M. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 62 (2002) 6823-6826
58. Carlsson H., Petersson S., and Enerback C. Cluster analysis of S100 gene expression and genes correlating to psoriasin (S100A7) expression at different stages of breast cancer development. Int. J. Oncol. 27 (2005) 1473-1481
59. Salama I., Malone P.S., Mihaimeed F., and Jones J.L. A review of the S100 proteins in cancer. Eur. J. Surg. Oncol. 34 (2008) 357-364
60. Ghavami S., Kerkhoff C., Los M., Hashemi M., Sorg C., and Karami-Tehrani F. Mechanism of apoptosis induced by S100A8/A9 in colon cancer cell lines: the role of ROS and the effect of metal ions. J. Leukoc. Biol. 76 (2004) 169-175
61. Wicki R., Franz C., Scholl F.A., Heizmann C.W., and Schafer B.W. Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site-specific hypermethylation. Cell Calcium 22 (1997) 243-254
62. Liu D., Rudland P.S., Sibson D.R., Platt-Higgins A., and Barraclough R. Expression of calcium-binding protein S100A2 in breast lesions. Br. J. Cancer 83 (2000) 1473-1479
63. Feng G., Ku X., Youssef E.M., and Lotan R. Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis. Cancer Res. 61 (2001) 7999-8004
64. Gupta S., Hussain T., MacLennan G.T., Fu P., Patel J., and Mukhtar H. Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma. J. Clin. Oncol. 21 (2003) 106-112
65. Ballester E., and Esteller M. Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger. Biochem. Cell. Biol. 83 (2005) 374-384
66. Ballester E., Paz M.F., Valle L., Wei S., Fraga M.F., Espada J., Cigudosa J.C., Huang T.H., and Esteller M. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 22 (2003) 6335-6345
67. Bolstad B.M., Irizarry R.A., Astrand M., and Speed T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19 (2003) 185-193